دورية أكاديمية
أعرض في EDS

Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer.

التفاصيل البيبلوغرافية
العنوان: Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer.
المؤلفون: Sjoberg HT; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK., Philippou Y; Department of Oncology, University of Oxford, Oxford, UK., Magnussen AL; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK., Tullis IDC; Department of Oncology, University of Oxford, Oxford, UK., Bridges E; Department of Oncology, University of Oxford, Oxford, UK., Chatrian A; Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK., Lefebvre J; Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK., Tam KH; Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK., Murphy EA; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.; Department of Oncology, University of Oxford, Oxford, UK., Rittscher J; Institute of Biomedical Engineering, Department of Engineering Science, University of Oxford, Oxford, UK.; Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Oxford, UK.; Target Discovery Institute, NDM Research Building, University of Oxford, Headington, UK., Preise D; Department of Core Facilities, The Weizmann Institute of Science, Rehovot, Israel., Agemy L; Department of Plant and Environmental Sciences, The Weizmann Institute of Science, Rehovot, Israel., Yechezkel T; Department of Plant and Environmental Sciences, The Weizmann Institute of Science, Rehovot, Israel., Smart SC; Department of Oncology, University of Oxford, Oxford, UK., Kinchesh P; Department of Oncology, University of Oxford, Oxford, UK., Gilchrist S; Department of Oncology, University of Oxford, Oxford, UK., Allen DP; Department of Oncology, University of Oxford, Oxford, UK., Scheiblin DA; Optical Microscopy and Analysis Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc. for the National Cancer Institute, National Institutes of Health, Frederick, MD, USA., Lockett SJ; Optical Microscopy and Analysis Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research Inc. for the National Cancer Institute, National Institutes of Health, Frederick, MD, USA., Wink DA; Cancer and Inflammation Program, Centre for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, USA., Lamb AD; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK., Mills IG; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK., Harris A; Department of Oncology, University of Oxford, Oxford, UK., Muschel RJ; Department of Oncology, University of Oxford, Oxford, UK., Vojnovic B; Department of Oncology, University of Oxford, Oxford, UK., Scherz A; Department of Plant and Environmental Sciences, The Weizmann Institute of Science, Rehovot, Israel., Hamdy FC; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK., Bryant RJ; Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK. richard.bryant@nds.ox.ac.uk.; Department of Oncology, University of Oxford, Oxford, UK. richard.bryant@nds.ox.ac.uk.
المصدر: British journal of cancer [Br J Cancer] 2021 Aug; Vol. 125 (4), pp. 534-546. Date of Electronic Publication: 2021 Jun 21.
نوع المنشور: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Nature Publishing Group on behalf of Cancer Research UK Country of Publication: England NLM ID: 0370635 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-1827 (Electronic) Linking ISSN: 00070920 NLM ISO Abbreviation: Br J Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: 2002- : London : Nature Publishing Group on behalf of Cancer Research UK
Original Publication: London, Lewis.
مواضيع طبية MeSH: Neovascularization, Pathologic/*therapy , Photochemotherapy/*methods , Prostatic Neoplasms/*therapy, Animals ; Cell Line, Tumor ; Combined Modality Therapy ; Dose Fractionation, Radiation ; Human Umbilical Vein Endothelial Cells ; Humans ; Male ; Mice ; Prostatic Neoplasms/blood supply ; Survival Analysis ; Tumor Microenvironment ; Xenograft Model Antitumor Assays
مستخلص: Background: There is a need to improve the treatment of prostate cancer (PCa) and reduce treatment side effects. Vascular-targeted photodynamic therapy (VTP) is a focal therapy for low-risk low-volume localised PCa, which rapidly disrupts targeted tumour vessels. There is interest in expanding the use of VTP to higher-risk disease. Tumour vasculature is characterised by vessel immaturity, increased permeability, aberrant branching and inefficient flow. FRT alters the tumour microenvironment and promotes transient 'vascular normalisation'. We hypothesised that multimodality therapy combining fractionated radiotherapy (FRT) and VTP could improve PCa tumour control compared against monotherapy with FRT or VTP.
Methods: We investigated whether sequential delivery of FRT followed by VTP 7 days later improves flank TRAMP-C1 PCa tumour allograft control compared to monotherapy with FRT or VTP.
Results: FRT induced 'vascular normalisation' changes in PCa flank tumour allografts, improving vascular function as demonstrated using dynamic contrast-enhanced magnetic resonance imaging. FRT followed by VTP significantly delayed tumour growth in flank PCa allograft pre-clinical models, compared with monotherapy with FRT or VTP, and improved overall survival.
Conclusion: Combining FRT and VTP may be a promising multimodal approach in PCa therapy. This provides proof-of-concept for this multimodality treatment to inform early phase clinical trials.
(© 2021. The Author(s).)
References: Clin Cancer Res. 2017 Jul 1;23(13):3343-3351. (PMID: 28108545)
Clin Cancer Res. 2018 May 15;24(10):2408-2416. (PMID: 29463549)
BJU Int. 2015 Dec;116(6):888-96. (PMID: 24841929)
Oncotarget. 2017 Jun 20;8(25):40115-40131. (PMID: 28445154)
Eur J Cancer. 2006 May;42(8):1062-7. (PMID: 16624554)
Br J Cancer. 2020 Sep;123(7):1089-1100. (PMID: 32641865)
J Urol. 2006 Aug;176(2):564-8. (PMID: 16813890)
Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):164-71. (PMID: 12007956)
Semin Radiat Oncol. 2003 Jan;13(1):53-61. (PMID: 12520464)
Int J Radiat Oncol Biol Phys. 1998 Nov 1;42(4):905-8. (PMID: 9845119)
Nature. 2013 Jul 11;499(7457):214-218. (PMID: 23770567)
Int J Radiat Oncol Biol Phys. 2001 Feb 1;49(2):443-50. (PMID: 11173139)
Int J Radiat Oncol Biol Phys. 1998 Nov 1;42(4):899-903. (PMID: 9845118)
Front Oncol. 2013 Aug 15;3:211. (PMID: 23967403)
PLoS One. 2010 Apr 22;5(4):e10282. (PMID: 20421983)
Radiother Oncol. 2019 Apr;133:16-19. (PMID: 30935573)
BJU Int. 2010 Jun;105(11):1536-40. (PMID: 19912180)
Photochem Photobiol Sci. 2011 May;10(5):681-8. (PMID: 21258718)
BJU Int. 2008 Aug 5;102(5):556-62. (PMID: 18494829)
Cell. 2011 Mar 4;144(5):646-74. (PMID: 21376230)
Cancers (Basel). 2020 Jan 02;12(1):. (PMID: 31906502)
Cancer. 2007 Apr 1;109(7):1273-8. (PMID: 17315165)
Eur Urol. 2014 Oct;66(4):732-51. (PMID: 23769825)
PLoS One. 2016 Nov 2;11(11):e0164920. (PMID: 27806062)
J Urol. 2007 Nov;178(5):1974-9; discussion 1979. (PMID: 17869307)
Urology. 2002 Sep;60(3 Suppl 1):57-62; discussion 62-3. (PMID: 12231051)
Nat Clin Pract Urol. 2009 Jan;6(1):18-30. (PMID: 19132003)
Br J Cancer. 2021 Aug;125(3):324-336. (PMID: 33828258)
Radiat Res. 2001 Nov;156(5 Pt 1):503-9. (PMID: 11604063)
Eur Urol. 2012 Jun;61(6):1096-106. (PMID: 22386839)
BJU Int. 2009 May;103(9):1173-8; discussion 1178. (PMID: 19040530)
Front Cardiovasc Med. 2018 Jun 27;5:78. (PMID: 29998128)
BJU Int. 2005 Apr;95(6):751-6. (PMID: 15794776)
Radiat Res. 2012 Mar;177(3):311-27. (PMID: 22229487)
Eur Urol. 2014 Feb;65(2):467-79. (PMID: 24321502)
Cancer Immunol Immunother. 2009 Jan;58(1):71-84. (PMID: 18488222)
Clin Cancer Res. 2009 Mar 1;15(5):1721-9. (PMID: 19240176)
Nat Rev Urol. 2020 Jun;17(6):321-338. (PMID: 32358562)
Urology. 2007 Jun;69(6):1170-5. (PMID: 17572209)
Magn Reson Imaging. 2015 Jul;33(6):847-51. (PMID: 25863135)
Int J Radiat Oncol Biol Phys. 2016 Jul 1;95(3):1022-1031. (PMID: 27130790)
Eur Urol. 2007 Oct;52(4):1058-65. (PMID: 17418938)
Biomed Res Int. 2013;2013:685308. (PMID: 23509762)
J Histochem Cytochem. 1989 Mar;37(3):315-21. (PMID: 2918221)
Lancet Oncol. 2017 Feb;18(2):181-191. (PMID: 28007457)
Cold Spring Harb Perspect Med. 2012 Mar;2(3):a006486. (PMID: 22393532)
Nat Rev Cancer. 2015 Jul;15(7):409-25. (PMID: 26105538)
J Radiat Res. 2012 Jul;53(4):570-80. (PMID: 22843622)
Eur Urol. 2017 Jan;71(1):17-34. (PMID: 27595377)
Oncotarget. 2016 Nov 22;7(47):76613-76627. (PMID: 27780936)
Surg Oncol. 2009 Sep;18(3):219-32. (PMID: 19268572)
Neuroimage. 2006 Jul 1;31(3):1116-28. (PMID: 16545965)
Int J Cancer. 2003 May 10;104(6):782-9. (PMID: 12640688)
World J Urol. 2015 Jul;33(7):945-53. (PMID: 25712310)
BJU Int. 2013 Oct;112(6):766-74. (PMID: 24028764)
J Urol. 2007 Aug;178(2):493-9; discussion 499. (PMID: 17561152)
Oncoimmunology. 2019 Mar 28;8(6):e1581528. (PMID: 31069149)
Phys Med Biol. 2008 May 7;53(9):2345-73. (PMID: 18421121)
معلومات مُعتمدة: 22748 United Kingdom CRUK_ Cancer Research UK; 25812 United Kingdom CRUK_ Cancer Research UK; 75N91019D00024 United States CA NCI NIH HHS
تواريخ الأحداث: Date Created: 20210622 Date Completed: 20211215 Latest Revision: 20240814
رمز التحديث: 20240814
مُعرف محوري في PubMed: PMC8367986
DOI: 10.1038/s41416-021-01450-6
PMID: 34155340
قاعدة البيانات: MEDLINE
الوصف
تدمد:1532-1827
DOI:10.1038/s41416-021-01450-6